Komal Jhaveri, MD, FACP, FASCO (@jhaveri_komal) ranks #18 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 9 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $162,904 in 2025 general payments.
At a Glance
- 3 colleague posts sharing slides from Komal Jhaveri, MD, FACP, FASCO's presentations
- Breast Cancer: US #18 · 9 physicians engaged
- Presented at ASCO 2026, SABCS 2025, ESMO 2026 in 2026
- CMS Open Payments lists $162,904 in 2025 general payments.
This Month
What Komal Jhaveri, MD, FACP, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #18 | — | 9 | 12 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Komal Jhaveri, MD, FACP, FASCO presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASCO 2026 · Abstract presentationPost-progression treatment analyses of evERA Breast Cancer: phase III giredestrant + everolimus in ER+, HER2- advanced BC previously treated with a CDK4/6 inhibitorEVERA trial profile → · Source: @MSKCancerCenter on X ↗
- SABCS 2025 · Abstract presentationEMBER-3 updates (imlunestrant)EMBER-3 trial profile → · Source: @hoperugo on X ↗
- ESMO 2026 · Invited lectureRefining endocrine therapy with CDK4/6 inhibitors in early breast cancerSource: @MSK_DeptOfMed on X ↗
What Colleagues Are Saying About Komal Jhaveri, MD, FACP, FASCO
2026 posts by fellow physicians that mention @jhaveri_komal, quoted word for word.
Many thanks to the @OncBrothers for allowing me to be a part of yet another terrific program at #ASCO26! Was thrilled to see my @cityofhope colleague @hoperugo after my panel w @TiansterZhang & @apolo_andrea. Bonus: Got to see the incredible @jhaveri_komal just before she graced the stage!
Promising PFS2 and OS data from evERA presented by @jhaveri_komal, showing clear improvement in outcomes with giredestrant/everolimus vs SoC ET/everolimus in ESR1mut disease, with a promising signal in ESR1wt patients as well. #ASCO26 https://t.co/VuVfz6Jpte
evERA BC at #ASCO26, presented by @jhaveri_komal, adds to a key question in ER+/HER2-negative advanced breast cancer: how should ESR1 testing guide sequencing when oral SERD combinations may benefit patients beyond ESR1-mutant disease? 🧬 Giredestrant + everolimus prolonged PFS2 and chemotherapy-free survival vs SOC endocrine therapy + everolimus, with a favorable interim OS trend. 📈 My takeaway: keep testing. ESR1 status still helps interpret benefit and guide sequencing among multiple post-CDK4/6i options. But SERD combinations should not be viewed as ESR1-only strategies.
📌 Post-progression treatment analyses of evERA Breast Cancer: A phase III trial of giredestrant + everolimus in patients with estrogen receptor-positive, HER2-negative advanced BC previously treated with a CDK4/6 inhibitor. Presented by @jhaveri_komal ✨🎙️#ASCO26 @OncoAlert #OncoAlertAF
Day 3 #ESMO26: @jhaveri_komal on refining adjuvant ET in ER+ EBC ✅ CDK4/6i: durable iDFS; OS benefit w/ abema, trend w/ ribo 🆕 lidERA: 1st positive adjuvant oral SERD (HR 0.70) 🧬 ctDNA/MRD: next frontier 🎯 Right drug, right time, right patient #BCSM #SLUHN 📋 If giredestrant is approved and CDK4/6i isn't an option (access, toxicity, preference), she'd strongly consider it. Stage I higher-risk: select cases. Stage II–III: CDK4/6i first, SERD after? Sequential trials read out from 2027. #OralSERD #BCSM 🏎️ ctDNA is like F1 telemetry: a real, early signal. In monarchE, 4-yr iDFS was 87.5% with persistently negative ctDNA, and 93% of patients whose ctDNA turned positive had an event. Does an early "pit stop" help? AFT-70 NAVIGATE is testing that. #ESMO26 #SLUHN 👩 In patients ≤40, CDK4/6i benefit held: iDFS HR 0.60 (monarchE) and 0.55 (NATALEE). No biomarker yet identifies who won't benefit. #BCSM #EndocrineTherapy @OncologyNetwork @JIPOEditors @myESMO @oncodaily
Komal Jhaveri, MD, FACP, FASCO’s Presentations
Slides from Komal Jhaveri, MD, FACP, FASCO’s 2026 presentations, as shared by physicians in the audience.
Promising PFS2 and OS data from evERA presented by @jhaveri_komal, showing clear improvement in outcomes with giredestrant/everolimus vs SoC ET/everolimus in ESR1mut disease, with a promising signal in ESR1wt patients as well. #ASCO26 https://t.co/VuVfz6Jpte
evERA BC at #ASCO26, presented by @jhaveri_komal, adds to a key question in ER+/HER2-negative advanced breast cancer: how should ESR1 testing guide sequencing when oral SERD combinations may benefit patients beyond ESR1-mutant disease? 🧬 Giredestrant + everolimus prolonged PFS2 https://t.co/wjeUfP1WLu
📌 Post-progression treatment analyses of evERA Breast Cancer: A phase III trial of giredestrant + everolimus in patients with estrogen receptor-positive, HER2-negative advanced BC previously treated with a CDK4/6 inhibitor. Presented by @jhaveri_komal ✨🎙️#ASCO26 @OncoAlert https://t.co/QmNOr7v17J
Komal Jhaveri, MD, FACP, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Super timely as FDA approved Dato in 1L metastatic TNBC for those who are not PD-1/PDL-1 I candidates based on the phase 3 TB-02 trial today! https://t.co/MaVU7jBIbv
Honored to be a #FASCO inductee at #ASCO26. Congratulations to all my fellow inductees @MSKCancerCenter @CliffordHudis @BurrisSkip @ErikaHamilton9 @drteplinsky https://t.co/j0gEcjIxpO
Industry Payments
CMS Open Payments · 2025 general payments
$162,904 across 85 payments